Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

Mark Warren^{1

2}, Michael Kolinsky^{1

3}, Christina M Canil^{4

5}, Piotr Czaykowski^{6

7}, Srikala S Sridhar⁸, Peter C Black⁹, Christopher M Booth¹⁰, Wassim Kassouf¹¹, Libni Eapen^{12

5}, Som D Mukherjee¹³, Normand Blais¹⁴, Bernhard J Eigl¹⁵, Eric Winquist¹⁶, Naveen S Basappa^{1

3}, Scott A North^{1

3}; GUMOC

Affiliations

¹ Department of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada.
² Cancer Center, Bendigo Health, Bendigo, Australia.
³ University of Alberta, Edmonton, AB, Canada.
⁴ The Ottawa Hospital Cancer Center, Ottawa, ON Canada.
⁵ Ottawa Hospital Research Institute, Ottawa, ON, Canada.
⁶ Cancer Care Manitoba, Winnipeg, MB, Canada.
⁷ University of Manitoba, Winnipeg, MB, Canada.
⁸ Division of Hematology and Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
⁹ Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.
¹⁰ Department of Oncology, Queen's University, Kingston, ON, Canada.
¹¹ Department of Surgery, McGill University Health Center, Montreal, QC, Canada.
¹² Division of Radiation Oncology, University of Ottawa, ON, Canada.
¹³ Juravinski Cancer Center, Hamilton, ON, Canada.
¹⁴ Division of Medical Oncology/Hematology, Centre Hospitalier de l' Université de Montréal, Montreal, Quebec, Canada.
¹⁵ BC Cancer, Vancouver, BC, Canada, University of British Columbia, BC, Canada.
¹⁶ Division of Medical Oncology, Western University and London Health Sciences Center, London, ON, Canada.

PMID: 31059420
PMCID: PMC6788915
DOI: 10.5489/cuaj.6015

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

Mark Warren et al. Can Urol Assoc J. 2019 Oct.

. 2019 Oct;13(10):318-327.

doi: 10.5489/cuaj.6015.

Authors

Affiliations

¹ Department of Medical Oncology, Cross Cancer Institute, Edmonton, AB, Canada.
² Cancer Center, Bendigo Health, Bendigo, Australia.
³ University of Alberta, Edmonton, AB, Canada.
⁴ The Ottawa Hospital Cancer Center, Ottawa, ON Canada.
⁵ Ottawa Hospital Research Institute, Ottawa, ON, Canada.
⁶ Cancer Care Manitoba, Winnipeg, MB, Canada.
⁷ University of Manitoba, Winnipeg, MB, Canada.
⁸ Division of Hematology and Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
⁹ Department of Urological Sciences, University of British Columbia, Vancouver, BC, Canada.
¹⁰ Department of Oncology, Queen's University, Kingston, ON, Canada.
¹¹ Department of Surgery, McGill University Health Center, Montreal, QC, Canada.
¹² Division of Radiation Oncology, University of Ottawa, ON, Canada.
¹³ Juravinski Cancer Center, Hamilton, ON, Canada.
¹⁴ Division of Medical Oncology/Hematology, Centre Hospitalier de l' Université de Montréal, Montreal, Quebec, Canada.
¹⁵ BC Cancer, Vancouver, BC, Canada, University of British Columbia, BC, Canada.
¹⁶ Division of Medical Oncology, Western University and London Health Sciences Center, London, ON, Canada.

PMID: 31059420
PMCID: PMC6788915
DOI: 10.5489/cuaj.6015

No abstract available

PubMed Disclaimer

Conflict of interest statement

All guidelines or consensus statements are current as of the date of writing and final editing but the field is constantly changing. As such, the current treatment landscape at time of publication may be different than what was in effect at the time a consensus statement was finalized.

Competing interests: Dr. Warren has received speaker honoraria from BI. Dr. Kolinsky has been a consultant for Janssen; has received honoraria/consulting fees/travel reimbursement from Astellas, AstraZeneca, BMS, Ipsen, Janssen, Merck, and Novartis; and has participated in clinical trials supported by Astellas, AstraZeneca, BMS, GSK, Ipsen, Janssen, Merck, and Roche. Dr. Canil has been an advisory board member for AstraZeneca, Bayer, BMS, Elsai, Ipsen, Janssen, Merck, Roche, and Sanofi Genzyme; has been speaker for Bayer; received travel grants from Amgen, Pfizer, and Sanofi Genzyme; is a member of the GU Research Council sponsored by industry; and has participated in clinical trials supported by AstraZeneca, Elsai, Janssen, and Roche. Dr. Czaykowski has participated in clinical trials supported by Clovis, Janssen, Merck, Millenium/Takeda, and MSD. Dr. Sridhar has been an advisory board member for Astellas, Astra Zeneca, Bayer, Janssen Merck, and Roche; and has participated in several clinical trials supported by industry. Dr. Black has been an advisory board member or equivalent for Abbvie, Asieris, Astellas, AstraZeneca, Bayer, Biosyent, BMS, Janssen, Lilly, Merck, Roche, Sanofi, and Urogen; has been a speaker for Abbvie, Biosyent, Ferring, Janssen, Pfizer, and TerSera; has received a grant(s) or honoraria from Bayer, GenomeDx Biosciences, iProgen, and Sanofi; has participated in clinical trials supported by Astellas, Ferring, Genentech, Janssen, MDx Health, and Sitka; and shares a patent with GenomeDx. Dr. Kassouf has received grants/honoraria from Astellas, AstraZeneca, Janssen, Merck, and Roche. Dr. Eapen has received honoraria from Abbott and AstraZeneca; and has participated in several clinical trials supported by industry. Dr. Mukherjee has been a speakers’ bureau member for AstraZeneca; has received honoraria from Amgen, AstraZeneca, Merck, Novartis, and Roche; and has participated in clinical trials supported by AstraZeneca and Roche. Dr. Blais has received honoraria for ad hoc consultancy with AstraZeneca, Bayer, BI, BMS, Merck, Novartis, Pfizer, Roche, Sanofi, and Servier. Dr. Eigl has received honoraria and travel support from Astellas, AstraZeneca, Bayer, Janssen, Merck, and Roche. Dr. Winquist has been an advisory board member for AstraZeneca, Merck, and Roche; and has participated in clinical trials supported by AstraZeneca, BMS, and Merck. Dr. Basappa has been an advisory board member for Astellas, AstraZeneca, BI, BMS, Jansse, Novartis, and Pfizer; and has received honoraria from Astellas, BMS, Janssen, Novartis, and Pfizer. Dr. North has been an advisory board member for Astellas; has received honoraria from Astellas, AstraZeneca, Janssen, Merck, Roche, and Sanofi; and has participated in clinical trials supported by AstraZeneca, Merck, Roche, and Sanofi.

References

1. Canadian Cancer Statistics Advisory Committee: Canadian Cancer Society. Canadian Cancer Statistics. Toronto, ON: 2018. [Accessed Feb. 20, 2019]. Available at: www.cancer.ca/en.
1. Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12:211–4. doi: 10.1016/S1470-2045(10)70275-8. - DOI - PubMed
1. Gonzalez CM, Jordan E, Zabor EC, et al. Split-dose cisplatin as an alternative to every-3-week dosing when using cisplatin/gemcitabine to treat advanced urothelial cancer. J Clin Oncol. 2015;33(7S):373. doi: 10.1200/jco.2015.33.7_suppl.373. - DOI
1. Morales-Barrera R, Bellmunt J, Suárez C, et al. Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 2012;48:1816–21. doi: 10.1016/j.ejca.2012.04.002. - DOI - PubMed
1. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602–8. doi: 10.1200/JCO.2005.07.757. - DOI - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

Affiliations

Canadian Urological Association/Genitourinary Medical Oncologists of Canada consensus statement: Management of unresectable locally advanced and metastatic urothelial carcinoma

Authors

Affiliations

Conflict of interest statement

References

LinkOut - more resources

Full Text Sources